Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs

This article was originally published in Start Up

Executive Summary

Over the past few years's there's been no shortage of venture capital investments in companies developing potential treatments for diseases of the eye. Still, investors continue to find entrepreneurs with innovative new approaches to treat age-related macular degeneration, glaucoma and other vision-imparing diseases.
Advertisement

Related Content

PanOptica Inc.
Venture Eyes Ophthalmology--And Likes What It Sees
Chakshu Research Inc.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007
Start-Up Previews (09/2007)
Alacrity Biosciences Inc.
Eyeon Therapeutics Inc.
An Eye for an Eye: Lucentis and the New Pharmaceutical Value System
Visible Progress in Devices for Age-Related Macular Degeneration
Ophthalmology's Next Frontier

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel